ProShare Advisors’s Crescent Biopharma CBIO Stock Holding History

ProShare Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-122	Closed	-$38K	–	2095
2020 Q3	$38K	Buy	122 +6	+5%	+$2.29K	﹤0.01%	1610
2020 Q2	$43K	Buy	+116	New	+$32.8K	﹤0.01%	1630
2020 Q1	–	Sell	-140	Closed	-$74K	–	1335
2019 Q4	$74K	Sell	140 -15	-10%	-$8.12K	﹤0.01%	1724
2019 Q3	$67K	Sell	155 -7	-4%	-$4.5K	﹤0.01%	1578
2019 Q2	$193K	Sell	162 -22	-12%	-$26.3K	﹤0.01%	1449
2019 Q1	$229K	Buy	184 +2	+1%	+$2.29K	﹤0.01%	1390
2018 Q4	$172K	Sell	182 -35	-16%	-$42.1K	﹤0.01%	1400
2018 Q3	$313K	Sell	217 -6	-3%	-$9.07K	﹤0.01%	1330
2018 Q2	$360K	Buy	223 +64	+40%	+$110K	﹤0.01%	1278
2018 Q1	$258K	Sell	159 -26	-14%	-$54.1K	﹤0.01%	1406
2017 Q4	$311K	Buy	+185	New	+$245K	﹤0.01%	1369

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ProShare Advisors's CBIO Position: Q4 2020 in Review

ProShare Advisors sold out of Crescent Biopharma (CBIO) in Q4 2020, closing a stake of 122 shares — an estimated $38K sold.

ProShare Advisors first reported a position in CBIO in Q4 2017 and held it in 11 quarters. The position peaked at $360K in Q2 2018. 89 funds tracked by Wall St. Rank hold CBIO as of Q4 2020.

ProShare Advisors reported no remaining Crescent Biopharma position as of Q4 2020 after selling out during the quarter.
ProShare Advisors sold 122 Crescent Biopharma shares in Q4 2020, an estimated $38K.
ProShare Advisors first reported a position in Crescent Biopharma in Q4 2017 and held it in 11 quarters.
ProShare Advisors's Crescent Biopharma position peaked at $360K in Q2 2018.
89 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2020.

Based on ProShare Advisors's 13F filing for Q4 2020, filed 9 Feb 2021.